SE Therapeutics develops a protein‑domain‑based platform that streamlines the manufacturing of cell and gene therapies for rare central nervous system and acute autoimmune disorders. By leveraging microbial mechanisms that naturally infiltrate human cells, the technology overcomes current scalability and workflow bottlenecks, making large‑scale production of complex biologics economically viable. This enables the development of treatments for hundreds of rare diseases that currently lack effective therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell and gene therapy manufacturing processes involve complex, labor‑intensive workflows that do not scale economically, limiting the production capacity needed for treating rare central nervous system and autoimmune diseases.
Solution
SE Therapeutics has created a protein‑domain platform based on microbial mechanisms that naturally enable entry into human cells. By integrating these self‑entering protein domains into therapeutic constructs, the platform simplifies cell and gene therapy manufacturing, reducing the number of processing steps and improving yields. This approach allows manufacturers to produce larger batches at lower cost, making advanced therapies more accessible for rare disease indications. The technology is compatible with existing production pipelines and can be applied to a range of therapeutic modalities, including CRISPR‑based editors and single‑chain antibodies.
Target Audience
Primary customers are cell and gene therapy manufacturers developing treatments for rare central nervous system disorders and acute autoimmune diseases.
Features
- Protein domains derived from naturally selected microbial entry mechanisms, providing intrinsic cell‑penetrating capability
- Compatibility with CRISPR‑Cas systems and single‑chain antibody formats to create self‑entering therapeutic agents
- Streamlined manufacturing workflow that reduces purification and formulation steps
- Enhanced production yields enabling scale‑up from pilot to commercial batch sizes
- Platform‑agnostic design that can be integrated into diverse cell and gene therapy pipelines